# ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection

> **NCT06342921** · PHASE2,PHASE3 · COMPLETED · sponsor: **Jiaxing AnDiCon Biotech Co.,Ltd** · enrollment: 749 (actual)

## Conditions studied

- Safety Issues
- Effect of Drug

## Interventions

- **DRUG:** 15 mg ADC189
- **DRUG:** 45 mg ADC189
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06342921
- **Lead sponsor:** Jiaxing AnDiCon Biotech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-07
- **Primary completion:** 2023-10-08
- **Final completion:** 2024-01-22
- **Target enrollment:** 749 (ACTUAL)
- **Last updated:** 2025-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06342921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06342921, "ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06342921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*